Antiepileptic drugs and brain development

Epilepsy Research

Volumn 88, Issue 1, 2010, Pages 11-22

  Ikonomidou, Chrysanthy ^a   Turski, Lechoslaw ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Anticonvulsants; Apoptosis; Development; Neurodegeneration; Neurogenesis; Synaptogenesis

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETIRACETAM; GABAPENTIN; HISTONE DEACETYLASE; ISOFLURANE; LAMOTRIGINE; MIDAZOLAM; NITROUS OXIDE; OXAZEPAM; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT THERAPY; APOPTOSIS; BRAIN DEVELOPMENT; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; EPILEPSY; EPILEPTIC STATE; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LEARNING DISORDER; LOW DRUG DOSE; MAZE TEST; MEMORY DISORDER; MYELIN DEFICIENCY; MYELINATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEURAL TUBE DEFECT; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SEIZURE; SYNAPTOGENESIS; TERATOGENESIS;

ANIMALS; ANTICONVULSANTS; BRAIN; COGNITION DISORDERS; EPILEPSY; FEMALE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 72249097937     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.09.019     Document Type: Review

References (112)

1. Asimiadou S., Bittigau P., Felderhoff-Mueser U., Manthey D., Sifringer M., Pesditschek S., Dzietko M., Kaindl A.M., Pytel M., Studniarczyk D., Mozrzymas J.W., and Ikonomidou C. Protection with estradiol in developmental models of apoptotic neurodegeneration. Ann. Neurol. 58 (2005) 266-276
2. Bashir Z.I., Bortolotto Z.A., Davies C.H., Berretta N., Irving A.J., and Seal A.J. Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature 363 (1993) 347-350
3. Bayer S.A., Altman J., Russo R.J., and Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14 (1993) 83-144
4. Bergey G.K., Swaiman K.F., Schrier B.K., Fitzgerald S., and Nelson P.G. Adverse effects of phenobarbital on morphological and biochemical development of fetal mouse spinal cord neurons in culture. Ann. Neurol. 9 (1981) 584-589
5. Bergman A., Feigenbaum J.J., and Yanai J. Neuronal losses in mice following both prenatal and neonatal exposure to phenobarbital. Acta Anat. 114 (1982) 185-192
6. Bignami G., Alleva E., Chiarotti F., and Laviola G. Selective changes in mouse behavioural development after prenatal benzodiazepine exposure: a progress resport. Prog. Neuropsychopharmacol. Biol. Psychiatry 16 (1992) 587-604
7. Bittigau P., Sifringer M., Genz K., Reith E., Pospischil D., Govindarajalu S., Dzietko M., Pesditschek S., Mai I., Dikranian K., Olney J.W., and Ikonomidou C. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15089-15094
8. Blank N.K., Nishimura R.N., and Seil F.J. Phenytoin neurotoxicity in developing mouse cerebellum in tissue culture. J. Neurol. Sci. 55 (1982) 91-97
9. Bolanos A.R., Sarkisian M., Yang Y., Hori A., Helmers S.L., and Mikati M. Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology 51 (1998) 41-48
10. Brooks W.J., Petit T.L., and LeBoutillier J.C. Effect of chronic administration of NMDA antagonists on synaptic development. Synapse 26 (1997) 104-113
11. Buehler B.A., Delimont D., van Waes M., and Finnell R.H. Prenatal prediction of risk of the fetal hydantoin syndrome. N. Engl. J. Med. 322 (1990) 1567-1572
12. Caceres A., Mautino J., and Kosik K.S. Suppression of MAP2 in cultured cerebellar macroneurons inhibits minor neurite formation. Neuron 9 (1992) 607-618
13. Cha B.H., Silveira D.C., Liu X., Hu Y., and Holmes G.L. Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res. 51 (2002) 217-232
14. Cilio M.R., Bolanos A.R., Liu Z., Schmid R., Yang Y., and Stafstrom C.E. Anticonvulsant action and long-term effects of gabapentin in the immature brain. Neuropharmacology 40 (2001) 139-147
15. Cohen J.A., Fisher R.S., Brigell M.G., Peyster R.G., and Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 41 (2000) 148-157
16. Cunnington M., and Tennis P. International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 64 (2005) 955-960
17. Diaz J., and Schain R.J. Phenobarbital: effects of long-term administration on behavior and brain of artificially reared rats. Science 199 (1978) 90-91
18. Dobbing J. The later development of the brain and its vulnerability. In: Davis J.A., and Dobbing J. (Eds). Scientific Foundations of Pediatrics (1974), Saunders, Philadelphia 565-577
19. Dobbing J., and Sands J. Comparative aspects of the brain growth spurt. Early Hum. Dev. 3 (1979) 79-83
20. Dobbing J., and Sands J. The quantitative growth and development of the human brain. Arch. Dis. Child. 48 (1993) 757-767
21. Dolk, H., Jentink, J., Loane, M., Morris, J., De Jong-van den Berg, L.T.W., on behalf of the EUROCAT Antiepileptic Drug Working Group, 2008. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 71, 714-722.
22. Emerit M.B., Riad M., and Hamon M. Trophic effects of neurotransmitters during brain maturation. Biol. Neonate 62 (1992) 193-201
23. Faiella A., Wernig M., Consalez G.G., Hostick U., Hoffman C., and Hustert E. A mouse model for valproate teratogenicity: parental effects, homeotic transformation, and altered HOX expression. Hum. Mol. Genet. 9 (2000) 227-236
24. File S.E., and Wilks L.J. Changes in seizure threshold and aggression during chronic treatment with three anticonvulsants and on drug withdrawal. Psychopharmacology (Berl.) 100 (1990) 237-242
25. Finnell R.H., Gelineau-van Waes J., Eudy J.D., and Rosenquist T.H. Molecular basis of environmentally induced birth defects. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 181-208
26. Fishman R.H.B., Ornoy A., and Yanai J. Ultrastructural evidence of long-lasting cerebellar degeneration after early exposure to phenobarbital in mice. Exp. Neurol. 79 (1983) 212-220
27. Fishman R.H., Ornoy A., and Yanai J. Correlated ultrastructural damage between cerebellum cells after early anticonvulsant treatment in mice. Int. J. Dev. Neurosci. 7 (1989) 15-26
28. Glier C., Dzietko M., Bittigau P., Jarosz B., Korobowicz E., and Ikonomidou C. Therapeutic doses of topiramate are not toxic to the developing brain. Exp. Neurol. 185 (2004) 403-409
29. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., and Giavara S. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 29 (2001) 6969-6978
30. Hansen H.H., Briem T., Dzietko M., Sifringer M., Rzeski W., Zdzisinska B., Thor F., Heumann R., Stepulak A., Bittigau P., and Ikonomidou C. Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol. Dis. 16 (2004) 440-453
31. Hardingham G.E., and Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 26 (2003) 81-89
32. Hatta T., Ohmori H., Murakami T., Takano M., Yamashita K., and Yasuda M. Neurotoxic effects of phenytoin on postnatal mouse brain development following neonatal administration. Neurotoxicol. Teratol. 21 (1999) 21-28
33. Hauser W.A. The prevalence and incidence of convulsive disorders in children. Epilepsia 35 Suppl. 2 (1994) S1-6
34. Henderson C.E. Programmed cell death in the developing nervous system. Neuron 17 (1996) 579-585
35. Hernandez-Diaz S., Smith C.R., Wyszynski D.P., and Holmes L.B. Malformations among infants exposed to carbamazepine during pregnancy. Birth Def. Res. (Part A): Clin. Mol. Teratol. 79 (2007) 357
36. Holley L.A., Turchi J., Apple C., and Sarter M. Dissociation between the attentional effects of infusions of a benzodiazepine receptor agonist and an inverse agonist into the basal forebrain. Psychopharmacology (Berl.) 120 (1995) 99-108
37. Holmes L.B., Harvey E.A., Coull B.A., Huntington K.B., Khoshbin S., Hayes A.M., and Ryan L.M. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. 344 (2001) 1132-1138
38. Holmes L.B., Wyszynski D.F., Baldwin E.J., et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Birth Def. Res. (Part A): Clin. Mol. Teratol. 76 (2006) 318
39. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vöckler J., Dikranian, Tenkova T., Stefovska V., Turski L., and Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
40. Ikonomidou C., Bittigau P., Ishimaru M.J., Koch C., Genz K., Price M.T., Stefovska V., Hörster F., Tenkova T., Dikranian K., and Olney J.W. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 287 (2000) 1056-1060
41. Ikonomidou C., Bittigau P., Koch C., Genz K., Hoester F., Felderhoff-Mueser U., Tenkova T., Dikranian K., and Olney J.W. Neurotransmitters and apoptosis in the developing brain. Biochem. Pharmacol. 62 (2001) 401-405
42. Ikonomidou C., Scheer J., Wilhelm T., Juengling F., Titze K., Stöver U., Lehmkuhl U., Koch S., and Kassubek J. Brain morphology alterations following prenatal exposure to antiepileptic drugs. Eur. J. Ped. Neurol. 11 (2007) 297-301
43. Ingram J.L., Peckham S.M., Tisdale B., and Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22 (2000) 319-324
44. Jackson G.D., Williams S.R., Weller R.O., van Bruggen N., Preece N.E., and Williams S.C. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res. 18 (1994) 57-66
45. Jensen F.E., Blume H., Alvarado S., Firkusny I., and Geary C. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia 36 (1995) 966-972
46. Jevtovic-Todorovic V., Hartman R.E., Izumi Y., Benshoff N.D., Dikranian K., and Zorumski C.F. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J. Neurosci. 23 (2003) 876-882
47. Johnson E.M., and Deckwerth T.L. Molecular mechanisms of developmental neuronal death. Annu. Rev. Neurosci. 16 (1993) 31-46
48. Jones K.L., Lacro R.V., Johnson K.A., and Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 320 (1989) 1661-1666
49. A-receptor mediated neurotransmission has long-term effects on the developing cerebral cortex. Mol. Cell. Proteomics Epub (2008)
50. Katz I., Kim J., Gale K.N., and Kondratyev A.D. Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. J. Pharmacol. Exp. Ther. 322 (2007) 494-500
51. Kellogg C.K. Sex differences in long-term consequences of prenatal diazepam exposure: possible underlying mechanisms. Pharmacol. Biochem. Behav. 64 (1999) 673-680
52. Kempermann G., and Volk B. Phenytoin inhibits expression of microtubule-associated protein 2 and influences cell-viability and neurite growth of cultured cerebellar granule cells. Brain Res. 687 (1995) 194-198
53. Kim J., Kondratyev A., and Gale K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J. Pharmacol. Exp. Ther. 323 (2007) 165-173
54. Koh S., and Jensen F.E. Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann. Neurol. 50 (2001) 366-372
55. Krafft K., Lyon D.O., and Poling A. Effects of phenytoin on schedule-controlled performance of rats. Psychopharmacology 78 (1982) 93-95
56. Laeng P., Pitts R.L., Lemire A.L., Drabik C.E., Weiner A., and Tang H. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J. Neurochem. 91 (2004) 238-251
57. Levitt P., Harvey J.A., Friedman E., Simansky B., and Murphy E.H. New evidence for neurotransmitter influences on brain development. Trends Neurosci. 20 (1997) 269-274
58. Luthi A., Schwyzer L., Mateos J.M., Gähwiler B.H., and McKinney R.A. NMDA receptor activation limits the number of synaptic connections during hippocampal development. Nat. Neurosci. 4 (2001) 1102-1107
59. Manent J.B., Jorquera I., Mazzucchelli I., et al. Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia 48 (2007) 684-693
60. Manthey D., Asimiadou S., Stefovska V., Kaindl A.M., Fassbender J., Ikonomidou C., and Bittigau P. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp. Neurol. 193 (2005) 497-503
61. Marsh E.D., Brooks-Kayal A.R., and Ported B.E. Seizures and antiepileptic drugs: does exposure alter normal brain development?. Epilepsia 47 (2006) 1999-2010
62. Martin M.L., and Regan C.M. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid G1 phase. Brain Res. 554 (1991) 223-228
63. Meador K.J., Baker G.A., and Finnelli R.H. In untero antiepileptic drug exposure. Fetal death and malformations. Neurology 67 (2006) 407-412
64. Meador K.L., Baker G., Cohen M.J., Gaily E., and Westerveld M. Cognitive/behavioral teratogenic effects of antiepileptic drugs. Epilepsy Behav. 11 (2007) 292-302
65. Mikati M.A., Holmes G.L., Chronopoulos A., Hyde P., Thurber S., and Gatt A. Phenobarbital modifies seizure-related brain injury in the developing brain. Ann. Neurol. 36 (1994) 425-433
66. Morrow J.I., Russell A., Gutherie E., Parsons L., Robertson I., Waddell R., Irwin B., Morrison P., McGivern C.R., and Craig J. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 77 (2006) 193-198
67. Neale E.A., Sher P.K., Granbard B.I., Habig M., Fitzgerald S.C., and Nelson P.G. Differential toxicity of chronic exposure to phenytoin, phenobarbital or carbamazepine in cerebral cortical cell cultures. Pediatr. Neurol. 1 (1985) 143-150
68. Nguyen L., Rigo J.M., Rocher V., Belachew S., Malgrange B., and Rogister B. Neurotransmitters as early signals for central nervous system development. Cell Tissue Res. 305 (2001) 187-202
69. Nicolai J., Vles J.S.H., and Aldenkamp A.P. Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: a critical review directed at structural study-bias. J. Neurol. Sci. 271 (2008) 1-14
70. Ogura H., Yasuda M., Nakamura S., Yamashita H., Mikoshiba K., and Ohmori H. Neurotoxic damage of granule cells in the dentate gyrus and the cerebellum and cognitive deficit following neonatal administration of phenytoin in mice. J. Neuropathol. Exp. Neurol. 61 (2002) 956-967
71. Ohmori H., Yamashita K., Hatta T., Yamasaki S., Kawamura M., and Hogashi Y. Effects of low-dose phenytoin administered to newborn mice on developing cerebellum. Neurotoxicol. Teratol. 19 (1997) 205-211
72. Ohmori H., Ogura H., Yasuda M., Nakamura S., Hatta T., and Kawano K. Developmental neurotoxicity of phenytoin on granule cells and Purkinje cells in mouse cerebellum. J. Neurochem. 72 (1999) 1497-1506
73. Olney J.W., Jevtovic-Todorovic V., and Ikonomidou C. Do pediatric drugs cause developing neurons to commit suicide?. Trends Pharmacol. Sci. 25 (2004) 135-139
74. Passingham R.E. Rates of brain development in mammals including man. Brain Behav. Evol. 26 (1985) 167-175
75. Patsalos P.N., and Wiggins R.C. Brain maturation following administration of phenobarbital, phenytoin, and sodium valproate to developing rats or to their dams: effects on synthesis of brain myelin and other subcellular membrane proteins. J. Neurochem. 39 (1982) 915-923
76. Paulson R.B., Sucheston M.E., Hayes T.G., and Paulson G.W. Teratogenic effects of valproate in the CD-1 mouse fetus. Arch. Neurol. 42 (1985) 980-983
77. Pawlikowski M., Ste{ogonek}pien H., Mróz-Wasilewska Z., and Pawlikowska A. Effects of diazepam on cell proliferation in cerebral cortex, anterior pituitary and thymus of developing rats. Life Sci. 40 (1987) 1131-1135
78. Pereira M.E., Rosat R., Huang C.H., Godoy M.G., and Izquierdo I. Inhibition by diazepam of the effect of additional training and of extinction on the retention of shuttle avoidance behavior in rats. Behav. Neurosci. 103 (1989) 202-205
79. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J. Biol. Chem. 276 (2001) 26724-26731
80. Phillips N.K., and Lockard J.S. Infant monkey hyperexcitability after prenatal exposure to antiepileptic compounds. Epilepsia 37 (1996) 991-999
81. Pick C.G., and Yanai J. Long-term reduction in eight arm maze performance after early exposure to phenobarbital. Int. J. Dev. Neurosci. 3 (1985) 223-227
82. Picker M., Thomas J., Koch C., and Poling A. Effects of phenytoin, phenobarbital, and valproic acid, alone and in selected combinations, on schedule-controlled behavior of rats. Pharmacol. Biochem. Behav. 22 (1985) 389-393
83. Qiao M., Malisza K.L., Del Bigio M.R., Kozlowski P., Seshia S.S., and Tuor U.I. Effect of long-term vigabatrin administration on the immature rat brain. Epilepsia 41 (2000) 655-665
84. Renfrey G., Schlinger H., Jakubow J., and Poling A. Effects of phenytoin and phenobarbital on schedule-controlled responding and seizure activity in the amygdala-kindled rat. J. Pharmacol. Exp. Ther. 248 (1989) 967-973
85. Retz W., Kornhuber J., and Riederer P. Neurotransmission and the ontogeny of human brain. J. Neural Transm. 103 (1996) 403-419
86. Rice D., and Barone S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ. Health Perspect. 208 (2000) 511-533
87. Rodier P.M. Chronology of neuron development: animal studies and their clinical implications. Dev. Med. Child Neurol. 22 (1980) 525-545
88. Rodier P.M. Vulnerable periods and processes during central nervous system development. Environ. Health Perspect. 102 Suppl. 2 (1994) 121-124
89. Rodier P.M. Developing brain as a target of toxicity. Environ. Health Perspect. 103 Suppl. 6 (1995) 73-76
90. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (2004) 553-564
91. Roger-Fuchs Y., Newman M.E., Trombka D., Zabalke E., and Yanai J. Hippocampal cholinergic alterations and related behavioral deficits after early exposure to phenobarbital. Brain Res. Bull. 29 (1992) 1-6
92. Rostock A., Hoffmann W., Siegemund C., and Bartsch R. Effects of carbamazepine, valproate calcium, clonazepam and piracetam on behavioral test methods for evaluation of memory-enhancing drugs. Methods Find Exp. Clin. Pharmacol. 11 (1989) 547-553
93. Schilling M.A., Inman S.L., Morford L.L., Moran M.S., and Vorhees C.V. Prenatal phenytoin exposure and spatial navigation in offspring: effects on reference and working memory and on discrimination learning. Neurotoxicol. Teratol. 21 (1999) 567-578
94. Serrano E.E., Kunis D.M., and Ransom B.R. Effects of chronic phenobarbital exposure on cultured mouse spinal cord neurons. Ann. Neurol. 24 (1988) 429-438
95. Shor S., Koren G., and Nulman I. Teratogenicity of lamotrigine. Can. Fam. Phys. 53 (2007) 1007-1009
96. Sidhu R.S., Del Bigio M.R., Tuor U.I., and Seshia S.S. Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain. Exp. Neurol. 144 (1997) 400-405
97. Smith D.F. Lithium and carbamazepine: effects on learned taste aversion and open field behavior in rats. Pharmacol. Biochem. Behav. 18 (1983) 483-488
98. Speidel B.D., and Meador S.R. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 308 (1972) 839-843
99. Stefovska V., Czuczwar M., Smitka M., Czuczwar P., Kis J., Kaindl A.M., Turski L., Turski W.A., and Ikonomidou C. Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann. Neurol. 64 (2008) 434-445
100. Strickler S.M., Dansky L.V., Miller M.A., Seni M.H., Andermann E., and Spielberg S.P. Genetic predisposition to phenytoin-induced birth defects. Lancet 2 (1985) 746-749
101. Titze K., Koch S., Helge H., Lehmkuhl U., Rauh H., and Steinhausen H.-C. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev. Med. Child Neurol. 50 (2008) 117-122
102. Trotter A., and Pohlandt F. The replacement of oestradiol and progesterone in very premature infants. Ann. Med. 32 (2000) 608-614
103. Vinten J., Adab N., and Kini U. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64 (2005) 949-954
104. Vorhees C.V. Fetal hydanthoin syndrome in rats: dose-effect relationships of prenatal phenytoin on postnatal development and behavior. Teratology 35 (1987) 287-303
105. Vorhees C.V. Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats. Psychopharmacology 92 (1987) 173-179
106. Vorhees C.V., and Minck D.R. Long-term effects of prenatal phenytoin exposure on offspring behavior in rats. Neurotoxicol. Teratol. 11 (1989) 295-305
107. Vorhees C.V., Acuff K.D., Weisenburger W.P., and Minck D.R. Teratogenicity of carbamazepine in rats. Teratology 41 (1990) 311-317
108. Webb S.J., Monk C.S., and Nelson C.A. Mechanisms of postnatal neurobiological development: implications for human development. Dev. Neurophychol. 19 (2001) 147-172
109. Wong W.T., and Wong R.O. Changing specificity of neurotransmitter regulation of rapid dendritic remodeling during synaptogenesis. Nat. Neurosci. 4 (2001) 351-352
110. Yan G.M., Irwin R.P., Liu S.Z., Weller M., Wood K.A., and Paul S.M. Diphenylhydanthoin induces apoptotic cell death of culture rat cerebellar granule neurons. J. Pharmacol. Exp. Ther. 274 (1995) 983-990
111. Yanai J., Fares F., Gavish M., Greenfeld Z., Katz Y., and Marcovici G. Neural and behavioral alterations after early exposure to phenobarbital. Neurotoxicology 10 (1989) 543-554
112. Zahn C.A. Neurologic care of pregnant women with epilepsy. Epilepsia 39 Suppl. 8 (1998) S26-31